D.E. Shaw & Co Portfolio holdings
D. E. Shaw & Co., L.P., founded in 1988 by David E. Shaw, a former Columbia University computer science professor, is a New York City-based global investment management firm renowned for pioneering quantitative investing, managing over $70 billion in assets as of late 2024. Starting with $28 million from Paloma Partners and private investors, the firm employs sophisticated mathematical models and proprietary algorithms—initially developed by a team of scientists and programmers—to exploit market anomalies across public and private markets, including equities, fixed income, and alternatives. Headquartered above a Greenwich Village bookstore in its early days, it now boasts over 2,500 employees across offices in North America, Europe, and Asia, led by a seven-member Executive Committee since Shaw stepped back in 2001 to focus on D. E. Shaw Research. Despite setbacks like the 1998 Russia debt crisis and the 2008 financial downturn, the firm has maintained a reputation for analytical rigor, risk management, and innovation, balancing its computational roots with discretionary strategies.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$862M |
| 2 |
Baidu
BIDU
|
+$752M |
| 3 |
Tencent Music
TME
|
+$426M |
| 4 |
Coca-Cola
KO
|
+$424M |
| 5 |
NVIDIA
NVDA
|
+$383M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$981M |
| 2 |
Wells Fargo
WFC
|
+$673M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$574M |
| 4 |
Moderna
MRNA
|
+$442M |
| 5 |
DuPont de Nemours
DD
|
+$415M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.93% |
| 2 | Consumer Discretionary | 10.48% |
| 3 | Healthcare | 8.56% |
| 4 | Communication Services | 8.41% |
| 5 | Financials | 6.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3001
CONMED
CNMD
$1.31B
| $970K | ﹤0.01% |
7,428
-8,506
| -53% | -$1.02M |
|
3002
Sutro Biopharma
STRO
$398M
| $970K | ﹤0.01% |
4,261
-5,602
| -57% | -$1.33M |
|
3003
Lemonade
LMND
$4.76B
| $968K | ﹤0.01% |
10,393
+1,469
| +16% | +$190K |
|
3004
Moelis & Co
MC
$5.04B
| $968K | ﹤0.01% |
+17,638
| New | +$945K |
|
|
ACC
3005
DELISTED
American Campus Communities, Inc.
ACC
| $968K | ﹤0.01% |
+22,421
| New | +$952K |
|
3006
CALL
Tenet Healthcare
THC
$21B
| $967K | ﹤0.01% |
+18,600
| New | +$940K |
|
3007
CALL
Establishment Labs
ESTA
$2.71B
| $963K | ﹤0.01% |
+15,400
| New | +$888K |
|
3008
Zentalis Pharmaceuticals
ZNTL
$321M
| $962K | ﹤0.01% |
22,171
-23,116
| -51% | -$995K |
|
|
VNET
3009
VNET Group
VNET
$2.04B
| $960K | ﹤0.01% |
+29,735
| New | +$1.1M |
|
3010
Steven Madden
SHOO
$3.18B
| $959K | ﹤0.01% |
25,750
-78,758
| -75% | -$2.87M |
|
3011
KLA
KLAC
$266B
| $958K | ﹤0.01% |
29,000
+650
| +2% | +$19.6K |
|
3012
PLDT
PHI
$4.26B
| $956K | ﹤0.01% |
36,554
+19,561
| +115% | +$547K |
|
3013
Revolution Medicines
RVMD
$40B
| $955K | ﹤0.01% |
+20,809
| New | +$933K |
|
|
AMRS
3014
CALL
DELISTED
Amyris Inc.
AMRS
| $955K | ﹤0.01% |
+50,000
| New | +$725K |
|
3015
Campbell Soup
CPB
$6.67B
| $953K | ﹤0.01% |
18,959
+9,737
| +106% | +$464K |
|
|
RDUS
3016
DELISTED
Radius Recycling
RDUS
| $953K | ﹤0.01% |
22,793
-53,679
| -70% | -$1.95M |
|
3017
PUT
FirstEnergy
FE
$28.5B
| $951K | ﹤0.01% |
27,400
| – | – |
|
|
ATSPU
3018
DELISTED
Archimedes Tech SPAC Partners Co. Unit
ATSPU
| $951K | ﹤0.01% |
+96,119
| New | +$951K |
|
3019
Brinker International
EAT
$8.38B
| $949K | ﹤0.01% |
+13,356
| New | +$893K |
|
|
ICPT
3020
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $949K | ﹤0.01% |
41,100
-72,600
| -64% | -$2.02M |
|
3021
CALL
Royal Gold
RGLD
$17.1B
| $947K | ﹤0.01% |
8,800
-27,200
| -76% | -$2.9M |
|
|
XONE
3022
CALL
DELISTED
The ExOne Company
XONE
| $944K | ﹤0.01% |
+30,100
| New | +$948K |
|
3023
Carriage Services
CSV
$635M
| $943K | ﹤0.01% |
26,786
-12,890
| -32% | -$447K |
|
|
CPLG
3024
DELISTED
CorePoint Lodging Inc. Common Stock
CPLG
| $942K | ﹤0.01% |
104,346
+53,408
| +105% | +$434K |
|
|
SBNY
3025
DELISTED
Signature Bank
SBNY
| $942K | ﹤0.01% |
+4,165
| New | +$821K |
|
Similar funds
D.E. Shaw & Co's Q1 2021 Portfolio in Review
As of Q1 2021, D.E. Shaw & Co held 4,712 positions worth $104B, down 7.4% from $112B the previous quarter. Its ten largest holdings account for 9.9% of the portfolio.
D.E. Shaw & Co withdrew a net $18.3B in Q1 2021, closing 730 positions and reducing 1,773 holdings. Its most notable exit was AstraZeneca, an estimated $214M position sold in full.
By sector, the portfolio is most concentrated in Technology at 16% of assets, up from 14% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, D.E. Shaw & Co opened a new position in Baidu worth $627M.
- D.E. Shaw & Co's largest Q1 2021 buy was Baidu: 2,881,724 shares worth $627M.
- D.E. Shaw & Co added most to Tesla in Q1 2021, an estimated $862M increase.
- D.E. Shaw & Co's biggest Q1 2021 reduction was Amazon, cutting an estimated $981M.
- D.E. Shaw & Co fully exited AstraZeneca in Q1 2021, selling an estimated $214M.
- D.E. Shaw & Co's ten largest holdings make up 9.9% of its $104B portfolio in Q1 2021.
- D.E. Shaw & Co opened 825 new positions and closed 730 in Q1 2021.
- D.E. Shaw & Co's portfolio value fell 7.4% quarter-over-quarter to $104B.
Based on D.E. Shaw & Co's 13F filing for Q1 2021, filed 17 May 2021.